Treatment of Geographic Atrophy With Subconjunctival Sirolimus: Results of a Phase I/II Clinical Trial

PURPOSE. To investigate the safety and effects of subconjunctival sirolimus, an mTOR inhibitor and immunosuppressive agent, for the treatment of geographic atrophy (GA). METHODS. The study was a single-center, open-label phase II trial, enrolling 11 participants with bilateral GA; eight participants...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Wong, Wai T., Dresner, Samuel, Forooghian, Farzin, Glaser, Tanya, Doss, Lauren, Zhou, Mei, Cunningham, Denise, Shimel, Katherine, Harrington, Molly, Hammel, Keri, Cukras, Catherine A., Ferris, Frederick L., Chew, Emily Y.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The Association for Research in Vision and Ophthalmology 2013
Konular:
Clinical Trials
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3638660/
https://ncbi.nlm.nih.gov/pubmed/23548622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1167/iovs.13-11650
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller